Skip to content

To study the genetic variation of Catechol-O Methyltransferase gene on chronic persistent surgical pain in patients undergoing open heart surgeries.

The influence of G472A Polymorphism of membrane bound Catechol-O Methyltransferase gene on chronic persistent surgical pain in patients undergoing open heart surgeries with median sternotomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/03/012364
Enrollment
216
Registered
2018-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Open heart surgerys

Interventions

Intervention1: nil: nil

Sponsors

SVIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age range: 18-65 years both male and female patients. 2. Undergoing coronary artery bypass grafting surgery (CABG) using the saphenous vein. 3. Undergoing cardiac valvular surgeries like aortic valve, mitral valve, combined valve surgeries (both aortic and mitral valve) with or without tricuspid annuloplasty. 4. Combined coronary artery and valve surgery. 5. American Society of Anesthesiologists Physical Status I, II & III.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing CABG by the separation of the internal mammary artery (IMA) 2. Patients with the history of analgesic addiction or drug abuse 3. Patients with pre-existing pain syndrome 4. Patients undergoing redo surgery or surgical re-exploration during the study period 5. Patients who received repeated revisions due to infection 6. Patients with intensive care unit stay of more than 7 days due to respiratory complications and wound infection 7. Postoperative wound infection. 8. Patients with neurological pathologies 9. Patients treated with antidepressant medication 10. Severe cardiovascular dysfunction(New York Heart Association class III or IV 11. Severe pulmonary, renal and hepatic disease 12. Inability to communicate and understand NRS( numerical rating scale) 13. Patients not willing to participate in the study 14. Patients unwilling to cooperate or will be unreachable for phone interviews will also be excluded.

Design outcomes

Primary

MeasureTime frame
Mutations will Identified , To analysis the levels of enzyme activity and m RNA levels.Timepoint: Mutations will be Identified , To analysis the levels of enzyme activity and m RNA levels with in two years.

Secondary

MeasureTime frame
Identified chronic persistent chronic painTimepoint: after three months

Countries

India

Contacts

Public ContactDr Alok Samantaray

SVIMS Sri Venkateswara Institute Of Medical Sciences

aloksvims@gmail.com9493547653

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026